ArticleFrontiers in cellular and infection microbiology2025
Identification of dominant peptide epitopes and antibody response to the spike protein of SARS-CoV-2.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Multiple antigenic epitopes are present in the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but they exhibit significant variation in immunogenicity and reactogenicity. We aimed to investigate the reactivity of different SARS-CoV-2 antigenic epitopes with serum antibodies from patients with COVID-19 and vaccinated individuals to characterize specific antibody responses. Methods: Linear B-cell peptides derived from the SARS-CoV-2 S protein were screened using the Immune Epitope Database (IEDB). These linear peptides were coupled to bovine serum albumin (BSA), and blot hybridization was used to investigate antigen-antibody reactions among the peptides, commercial anti-S protein polyclonal antibodies, and sera derived from vaccinated individuals and those with confirmed COVID-19. Sera from unvaccinated patients and BSA served as controls. Results: Six linear B-cell peptide epitopes were identified from the IEDB and designated as P1-P6. Among these, P6 (aa 809-826) demonstrated stronger reactivity with rabbit anti-SARS-CoV-2 S polyclonal antibodies than the others. Antibodies against P2 (aa 553-570) were detected in the early stages of infection in four patients with confirmed COVID-19, and two of them developed antibodies against P5 (aa 601-640) later during the middle or late stages. Antibody responses against P1 (aa 209-226), P3 (aa 769-786), P4 (aa 287-317), and P6 were either extremely weak or undetected in patients with confirmed COVID-19. Sera from 45 individuals immunized with the inactivated vaccine were tested for reactivity against the six peptides. Antibody signals against P2, P5, and P6 were detected either individually or in combination, with P2 showing the highest frequency, followed by P6 and P5. Antibodies against P1, P3, and P4 were not detected. Six predicted B-cell dominant peptides exhibited distinct immunogenicity and reactogenicity, with P2 (aa 553-570) eliciting the strongest response. Antibody profiles against S protein epitopes differed between individuals infected with SARS-CoV-2 and those vaccinated with inactivated vaccines. Conclusion: The peptide combination of P2, P5, and P6 shows potential for the development of peptide-based target antigens for SARS-CoV-2 serological antibody diagnostic reagents, and reveals the response patterns of antibodies against SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.